Clinical Trial Update: Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) [Phase 1, Phase 2]

View source ↗

Summary

An update on a Phase 1/Phase 2 trial of MEPL-G (mitoxantrone liposome, etoposide, dexamethasone, pegaspargase, and golodocitinib) for extranodal NK/T-cell lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma
• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Etoposide (Etoposide)
• Golidocitinib (golidocitinib)
• Mitoxantrone Liposome (mitoxantrone liposome)
• Pegaspargase (pegaspargase)

Snippet

Sponsor: Beijing Tongren Hospital | Conditions: Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH) | Phase 1, Phase 2 | Status: RECRUITING